Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor ...

Hookipa Pharma (NASDAQ:HOOK – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ...

RBC Capital的分析师已将HOOKIPA Pharma的股票评级从"优于大市"下调至"与大市同步"，并大幅下调目标价，从48.00美元降至2.00美元。此次降级是在HOOKIPA宣布重组计划之后做出的，该计划包括裁减80%的员工，并暂停其主要项目的临床开发。RBC ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly withdrew from negotiations. The news was announced in a stock exchange ...

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky ...

Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg and the announcement on 30 January 2025 regarding the PUSU ...

Hookipa Pharma (HOOK) (ISIN: US43906K2096)股票专题，提供今日Hookipa Pharma(HOOK) (ISIN: US43906K2096)股票最新股价查询，实时市场行情，走势图表，及Hookipa Pharma Inc(HOOK) (ISIN: US43906K2096)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

HOOKIPA Pharma Inc. announced that it will not proceed with a planned all-share acquisition of Poolbeg Pharma plc, as discussed in previous communications. This decision follows non-binding ...

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United ...